Search
- Dec 7, 2023
Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics
Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A